CorMedix Q3 revenue beats expectations
CorMedix beat Q3 2026 Wall Street expectations announcing $54.5M in consolidated revenue and a narrowed adjusted EBITDA outlook.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed